Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis

doi:10.5306/wjco.v16.i8.106873

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

(56)

(63)

(0)

(1292)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Clin Oncol. Aug 24, 2025; 16(8): 106873
Published online Aug 24, 2025. doi: 10.5306/wjco.v16.i8.106873

Full Size Figure Download Figure

Figure 2 Forest plot of the meta-analysis for survival outcomes in the intention-to-treat cohort. A: Progression-free survival; B: Overall survival. HR: Hazard ratio; CI: Confidence interval; SOC: Standard-of-care; PD-1/L1:Programmed death 1 or its ligand.

Citation: Zheng T, Li XX, Zhou L, Jin JJ. Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis. World J Clin Oncol 2025; 16(8): 106873
URL: https://www.wjgnet.com/2218-4333/full/v16/i8/106873.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i8.106873

Zheng T, Li XX, Zhou L, Jin JJ. Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis. World J Clin Oncol 2025; 16(8): 106873 [PMID: 40901310 DOI: 10.5306/wjco.v16.i8.106873]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.